Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 17Breast 11Tumor-Agnostic 10Lymphoid 5Thoracic 4Dermatologic 4Genitourinary 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2Plasma cell 1Myeloid 1Classical hematology 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 66Lung Neoplasms 26Small Cell Lung Carcinoma 10Pancreatic Neoplasms 6Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Squamous Cell 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Carcinoma, Pancreatic Ductal 3Adenocarcinoma of Lung 3Sarcoma 2Recurrence 2Rectal Neoplasms 2Prostatic Neoplasms 2NSCLC 2Melanoma 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2Tumor Virus Infections 1

Interventions

pembrolizumab 48Carboplatin 34Pemetrexed 28Cisplatin 25Docetaxel 23Nivolumab 21Paclitaxel 20Gemcitabine 15Magnetic Resonance Spectroscopy 14Specimen Handling 12Radiotherapy 12Cyclophosphamide 12Radiosurgery 11130-nm albumin-bound paclitaxel 11Erlotinib Hydrochloride 10Bevacizumab 10osimertinib 9Cetuximab 8Temozolomide 7Taxes 7Ipilimumab 7Biopsy 7fludarabine 6Ramucirumab 6Radiation 6veliparib 5tislelizumab 5durvalumab 5cemiplimab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Albumin-Bound Paclitaxel × Thoracic × Clear all
NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phanes Therapeutics

Phase 1/2 Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

Phase 1 Terminated
159 enrolled
DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT02799862 2021-10-06

NEPTUN

iOMEDICO AG

Completed
408 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡